SearcharxivSearch

arXiv · 1602.08111

A Cancer Biotherapy Resource

Abstract

Cancer Biotherapy (CB), as opposed to cancer chemotherapy, is the use of macromolecular, biological agents instead of organic chemicals or drugs to treat cancer. Biological agents usually have higher selectivity and have less toxic side effects than chemical agents. The I.S.B.T.C., being the only major information database for CB, seems lacking in some crucial information on various cancer biotherapy regimens. It is thus necessary to have a comprehensive curated CB database. The database accessible to cancer patients and also should be a sounding board for scientific ideas by cancer researchers. The database/web server has information about main families of cancer biotherapy regimens to date, namely, Protein Kinase Inhibitors, Ras Pathway Inhibitors, Cell-Cycle Active Agents, MAbs (monoclonal antibodies), ADEPT (Antibody-Directed Enzyme Pro-Drug Therapy), Cytokines, Anti-Angiogenesis Agents, Cancer Vaccines, Cell-based Immunotherapeutics, Gene Therapy, Hematopoietic Growth Factors, Retinoids, and CAAT. For each biotherapy regimen, we will extract the following attributes in populating the database: Cancer type, Gene/s and gene product/s involved, Gene sequence, Organs affected, Reference papers, Clinical phase/stage, Survival rate, Clinical test center locations, Cost, Patient blogs, Researcher blogs, and Future work. The database will be accessible to public through a website and had FAQs for making it understandable to the laymen and discussion page for researchers to express their views and ideas. In addition to information about the biotherapy regimens, the website will link to other biologically significant databases like structural proteomics, metabolomics, glycomics, and lipidomics databases, as well as to news around the world regarding cancer therapy results. The database attributes would be regularly updated for novel attributes as discoveries are made.

Explore related subjects

Keep this discovery

BibTeXRIS

Preety Priya, Vicente M. Reyes. 2015-12-15. A Cancer Biotherapy Resource. https://arxiv.org/abs/1602.08111

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related papers

Sequence-Informed Geometric Evaluation of RNA 3D Structures

Computational RNA structure pipelines generate many candidate conformations for the same sequence. Reliable evaluation therefore requires more than recognising plausible geometry, it requires determining whether that geometry is compatible with the sequence. We introduce SIRGE, a sequence-informed geometric evaluator that conditions structural representations on nucleotide embeddings from a pretrained RNA language model. Early results show that SIRGE outperforms established evaluators in Kendall--$\tau$ alignment, Top-1 selection, and Top-3 ranking. Controlled comparisons further show that sequence conditioning corrects errors made by an otherwise matched geometric model and improves target-level rank structure. These findings provide initial evidence that pretrained sequence representations supply ranking information that complements geometric reasoning.

q-bio.BM

PocketVE: Stable and Property-Guided Structure-Based Drug Design with Variance-Exploding Diffusion

Protein-conditioned 3D molecule generation is a central challenge in structure-based drug design, requiring a balance between pocket compatibility, molecular properties, and physical geometry. We propose \textbf{PocketVE}, a protein-pocket-conditioned variance-exploding (VE) diffusion framework that couples stable coordinate denoising with inference-time property guidance. Specifically, PocketVE combines an EDM-style training and sampling setup for 3D denoising, classifier-free guidance for multi-property steering without external property classifiers, and adaptive protein perturbation as a training-time pocket regularizer. Evaluated on CrossDocked2020 under the GenBench3D protocol, PocketVE improves Valid$_{3\text{D}}$ from 58.6 to 80.6 and reduces strain energy from 457.4 to 127.9 relative to its TAGMol architectural baseline, while retaining competitive docking and molecular-property scores under moderate guidance. A guidance-scale study shows that moderate guidance gives a favorable balance between target-related objectives and geometric quality, whereas stronger guidance can degrade geometry and distributional fidelity. Pocket-permutation and PoseCheck diagnostics further support pocket-specific spatial compatibility with reduced steric conflicts. Overall, the results suggest that geometric stability and inference-time property guidance should be considered as coupled design objectives.

q-bio.BM

Predicting directional flexibility in proteins

Predicting protein dynamics is a long-standing problem in computational structural biology. Often, protein function critically depends on local directed motions, such as hinge movements, catalytic loop rearrangements and domain reorientations, which can be characterized by directional flexibility and correlated structural motions of the protein backbone. While Molecular Dynamics (MD) simulations provide an established but often prohibitively expensive approach, recent deep generative models aim to reduce this cost by directly predicting conformational ensembles, emulating MD. However, due to their large size and the need to generate several states until the derived dynamical properties converge, these models remain expensive. In this work, we propose BackFlip-2: a fast SE(3)-equivariant graph neural network trained to directly predict dynamical descriptors, such as directional backbone flexibility and pairwise dynamic correlations, from an equilibrium structure. In a series of experiments, we show that our model matches the accuracy of substantially larger ensemble generation models while being orders of magnitude faster, and demonstrate that the proposed equivariant architecture is especially well-suited for capturing anisotropic motions in proteins. BackFlip-2 model weights, training and inference code are available at https://github.com/graeter-group/backflip.

q-bio.BM